In line with the observations reported for sotorasib, Briere et al. recently outlined, in KRAS G12C syngeneic and genetically engineered mouse models, adagrasib decreases intra-tumor MDSCs while it increases M1-macrophages, dendritic cells and CD4+/CD8+ T-cells (94). Here, CD8A is linked to neoplasm.